UT-MD Anderson Cancer Center: Targeted Therapy Momelotinib Provides Significant Symptom And Anemia Improvements In Patients With Myelofibrosis
January 27, 2023
January 27, 2023
HOUSTON, Texas, Jan. 27 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase III study reports meaningful benefits over standard therapy
* * *
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOME . . .
* * *
Phase III study reports meaningful benefits over standard therapy
* * *
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOME . . .